LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Strona główna・Stock List・MannKind Corp

MannKind Corp

Closed

SectorHealthcare

3.51 -0.85

Buy Sell

Overview

Share price change

24h

Current

Min

3.4

Max

3.67

Key metrics
By Trading Economics
Income	-24M -16M
Sales	30M 112M
P/E Sector Avg	140.5 49.8
EPS	0.01
Profit margin	-14.245
Employees	591
EBITDA	-20M -2.5M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+112.39% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	-689M 868M
Previous open	4.36
Previous close	3.51

News Sentiment

By Acuity

30%

70%

92 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

4.079 / 4.323 Support & Resistance

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 maj 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 maj 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 maj 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 maj 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 maj 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 maj 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 maj 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 maj 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 maj 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 maj 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 maj 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 maj 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 maj 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 maj 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 maj 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 maj 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 maj 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 maj 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 maj 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 maj 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 maj 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 maj 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8 maj 2026, 15:20 UTC

Market Talk

Earnings

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 maj 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 maj 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 maj 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

112.39% upside

12 Months Forecast

Average 7.54 USD 112.39%

High 10 USD

Low 4.75 USD

Based on 8 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

92 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.